Results 291 to 300 of about 1,395,710 (388)

Estimated annual direct medical costs of manifestations among patients with activated phosphoinositide 3-kinase delta syndrome. [PDF]

Clin Exp Med
Hartog NL, Wu EY, Rider NL, Meng Y, Hartline B, Adams P, Aggarwal S, Harrington A.   +7 more
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Case Report: Sequential lymphomas: may HLA system play a role in this uncommon phenomenon? [PDF]

Front Oncol
Verrou E, Diamanti I, Fylaktou A, Daiou A, Dalampira D, Dimitriadou X, Tara V, Karadrakonti E, Triantafyllou T, Sevastoudi A, Vlachaki E, Karampatzakis N, Papadopoulou T, Sinakos E, Katodritou E, Gioula G.   +15 more
europepmc   +1 more source

Hodgkin lymphoma

, 2012
openaire   +1 more source

The prevalence of polypharmacy increases with age among patients with inflammatory bowel disease: A nationwide cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Polypharmacy is common in adult patients with inflammatory bowel disease (IBD). This study aims to quantify medication prescriptions and estimate the risk of polypharmacy over time in older adults with IBD. Methods In a nationwide cohort of adult incident IBD patients from 1 April 1996, to 31 December 2019, we examined medication prescriptions ...
Ken Lund, Jesper Ryg, Torben Knudsen, Jens Kjeldsen, Jan Nielsen, Sonia Friedman, Jimmy K. Limdi, Bente Mertz Nørgård   +7 more
wiley   +1 more source

Clinical Characteristics, Prognostic Risk Factors, and Primary Treatment for Elderly Patients with Primary Central Nervous System Lymphoma: A Seer Database-Based Research. [PDF]

Blood Lymphat Cancer
Zhang M, Yang R, Du Y, Feng H, Liu Y, Liu H, Wu D, Niu F, He P.   +8 more
europepmc   +1 more source

The Occurrence of Malignant Lymphomas in Urethan-treated Swiss Mice

, 1961
Béla Tóth, Gilda Porta, Philippe Shubik   +2 more
openalex   +1 more source

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

Science Translational Medicine, 2016
F. Scherer, D. Kurtz, Aaron M. Newman, H. Stehr, A. Craig, M. S. Esfahani, A. Lovejoy, J. Chabon, D. Klass, C. Liu, Li Zhou, Cynthia Glover, B. Visser, G. Poultsides, R. Advani, L. Maeda, Neel K. Gupta, R. Levy, R. Ohgami, C. Kunder, M. Diehn, Ash A. Alizadeh   +21 more
semanticscholar   +1 more source

Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability‐enhancing strategies

British Journal of Clinical Pharmacology, EarlyView.
Aims The study aims to predict and improve the absorption of tyrosine kinase inhibitors (TKIs) in patients with malabsorption issues, particularly those who have undergone bariatric surgery or are using proton‐pump inhibitors. The research involves 2 main components: the development of an artificial intelligence (AI) model to identify TKIs that are ...
Daan W. Huntjens, Olivier J. M. Béquignon, Stefanie D. Krens, Mark Löwenberg, Martine E. D. Chamuleau, Remco J. Molenaar, Anita M. G. Kramers, Marianne A. Kuijvenhoven, Imke H. Bartelink   +8 more
wiley   +1 more source

Plasma Cell Crystalline Inclusions in ALK-Negative Anaplastic Large Cell Lymphoma. [PDF]

EJHaem
Kinoshita H, Satoh T, Kayano H, Takahashi N, Ebihara Y.   +4 more
europepmc   +1 more source